Severity of Left Ventricular Dysfunction in Patients With Tachycardia-Induced Cardiomyopathy: Impacts on Remodeling After Atrial Flutter Ablation

被引:1
作者
De Larochellie, Hugo [1 ]
Brouillette, Francois [1 ]
Levesque, Patrick [1 ]
Dognin, Nicolas [1 ]
St-Germain, Raphael [1 ]
Rimac, Goran [1 ]
Lemay, Sylvain [1 ]
Philippon, Francois [1 ]
Senechal, Mario [1 ]
机构
[1] Univ Laval, Inst Univ Cardiol & Pneumol Quebec IUCPQ, Div Cardiol, Quebec City, PQ, Canada
关键词
ablation; atrial flutter; remodeling; tachycardia-induced cardiomyopathy; CATHETER ABLATION; FIBRILLATION; PREDICTORS; RECOVERY; SECONDARY;
D O I
10.1016/j.amjcard.2023.11.072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tachycardia-induced cardiomyopathy is defined as a reversible left ventricular (LV) systolic dysfunction (SeD) resulting from a sustained fast heart rate. LV remodeling in patients with severe LV dysfunction at diagnosis remains poorly understood. In this retrospective cohort study, we described LV remodeling in 50 patients who underwent atrial flutter ablation. These patients were divided into severe LV SeD (LV ejection fraction [EF] <= 30%) and LV nonsevere SeD (LVEF 31% to 50%) at baseline. All continuous variables are expressed as median and interquartile range. LVEF was 18% (13 to 25) and 38% (34 to 41) in the SeD (n = 29) and LV nonsevere SeD (n = 21) groups, respectively. At baseline, patients with SeD had higher LV end-diastolic diameter (56 [54 to 59] vs 49 mm [47 to 52], p <0.01), LV end-systolic diameter (48 [43 to 51] vs 36 mm [34 to 41], p <0.01), LV end-diastolic volume (71 [64 to 85] vs 56 ml/m(2) [46 to 68], p <0.01), LV end-systolic volume (56 [53 to 70] vs 36 ml/m(2) [27 to 42], p <0.01), and lower tricuspid annular plane systolic excursion (12 [10 to 13] vs 16 mm [13 to 19], p <0.01). At last follow-up, LVEF was not statistically significantly different between groups. However, LV end-systolic diameter (36 [34 to 39] vs 32 mm [32 to 34], p = 0.01) and LV end-systolic volume (29 [26 to 35] vs 25 ml/m(2) [20 to 29], p = 0.02) remained larger in the SeD group. Seven patients (14%), all from the SeD group, had a LVEF <= 35% 2 months after rhythm control, and reverse remodeling was observed up to 9 months. In conclusion, more than half of patients with tachycardia-induced cardiomyopathy and atrial flutter had LVEF <= 30% at baseline. LVEF recovery and LV remodeling were observed beyond 2 months, highlighting the importance of rhythm control and early guideline-directed medical therapy in these patients.
引用
收藏
页码:132 / 139
页数:8
相关论文
共 29 条
  • [1] Echocardiographic changes and heart failure hospitalizations following rhythm control for arrhythmia-induced cardiomyopathy: results from a multicenter, retrospective study
    Ahmad, Ali
    Mar, Philip L.
    Olshansky, Brian
    Horbal, Piotr
    Tsai, Christina
    Patel, Hiren
    Hussein, Ahmed
    Dickey, Sierra
    Dhawan, Rahul
    Murray, Andrew
    Lakkireddy, Dhanunjaya
    Gopinathannair, Rakesh
    [J]. JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2023, 66 (02) : 455 - 462
  • [2] Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation
    Brembilla-Perrot, Beatrice
    Ferreira, Joao Pedro
    Manenti, Vladimir
    Sellal, Jean Marc
    Olivier, Arnaud
    Villemin, Thibaut
    Beurrier, Daniel
    De Chillou, Christian
    Louis, Pierre
    Brembilla, Alice
    Juilliere, Yves
    Girerd, Nicolas
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (04) : 394 - 401
  • [3] Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing pulmonary vein isolation
    Calvo, Naiara
    Bisbal, Felipe
    Guiu, Esther
    Ramos, Pablo
    Nadal, Merce
    Maria Tolosana, Jose
    Arbelo, Elena
    Berruezo, Antonio
    Sitges, Marta
    Brugada, Josep
    Mont, Lluis
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (04) : 4093 - 4097
  • [4] The clinical, electrocardiographic and echocardiographic characteristics and long-term outcome of patients with tachycardia-induced cardiomyopathy
    Chin, Ashley
    Badri, Motasim
    Ntusi, N. B.
    Okreglicki, Andrzej
    [J]. CARDIOVASCULAR JOURNAL OF AFRICA, 2012, 23 (03) : 136 - 142
  • [5] DAMIANO RJ, 1987, J THORAC CARDIOV SUR, V94, P134
  • [6] Catheter Ablation of Atrial Fibrillation in Patients with Concomitant Left Ventricular Impairment: a Systematic Review of Efficacy and Effect on Ejection Fraction
    Ganesan, Anand N.
    Nandal, Savvy
    Lueker, Jakob
    Pathak, Rajeev K.
    Mahajan, Rajiv
    Twomey, Darragh
    Lau, Dennis H.
    Sanders, Prashanthan
    [J]. HEART LUNG AND CIRCULATION, 2015, 24 (03) : 270 - 280
  • [7] Gopinathannair R, 2021, J CARDIOVASC ELECTR, V32, P1085, DOI [10.1111/jce.14963, 10.1080/15440478.2021.1929654, 10.1080/15440478.2021.1964133]
  • [8] Catheter ablation for atrial fibrillation in congestive heart failure
    Hsu, LF
    Jaïs, P
    Sanders, P
    Garrigue, S
    Hocini, M
    Sacher, F
    Takahashi, Y
    Rotter, M
    Pasquié, J
    Scavée, C
    Bordachar, P
    Clémenty, J
    Haïssaguerre, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (23) : 2373 - 2383
  • [9] Arrhythmia-Induced Cardiomyopathy JACC State-of-the-Art Review
    Huizar, Jose F.
    Ellenbogen, Kenneth A.
    Tan, Alex Y.
    Kaszala, Karoly
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (18) : 2328 - 2344
  • [10] Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy
    Hyman, Matthew C.
    Mustin, Danielle
    Supple, Gregory
    Schaller, Robert D.
    Santangeli, Pasquale
    Arkles, Jeffrey
    Lin, David
    Muser, Daniele
    Dixit, Sanjay
    Nazarian, Saman
    Epstein, Andrew E.
    Callans, David J.
    Marchlinski, Francis E.
    Frankel, David S.
    [J]. HEART RHYTHM, 2018, 15 (02) : 159 - 163